LU92992I2 - Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables - Google Patents

Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables Download PDF

Info

Publication number: LU92992I2
Authority: LU; Luxembourg
Prior art keywords: pharmaceutically acceptable; hypertension; diabetic; renal; primary
Prior art date: 1998-07-10

Application number

LU92992C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

2016-03-07

Publication date

2016-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92992(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-07 Application filed by Novartis Ag filed Critical Novartis Ag

2016-05-09 Publication of LU92992I2 publication Critical patent/LU92992I2/fr

Links

150000003839 salts Chemical class 0.000 title abstract 3
229940043102 valsartan and amlodipine Drugs 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 3
206010012601 diabetes mellitus Diseases 0.000 abstract 3
206010002383 Angina Pectoris Diseases 0.000 abstract 2
206010019280 Heart failures Diseases 0.000 abstract 2
208000001647 Renal Insufficiency Diseases 0.000 abstract 2
201000006370 kidney failure Diseases 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010003662 Atrial flutter Diseases 0.000 abstract 1
239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
208000007530 Essential hypertension Diseases 0.000 abstract 1
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
206010039710 Scleroderma Diseases 0.000 abstract 1
206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
206010042600 Supraventricular arrhythmias Diseases 0.000 abstract 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
201000001474 proteinuria Diseases 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
229960004699 valsartan Drugs 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Hydrogenated Pyridines (AREA)

LU92992C 1998-07-10 2016-03-07 Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables LU92992I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11389398A	1998-07-10	1998-07-10
EP99934647A EP1096932B1 (fr)	1998-07-10	1999-07-09	Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium
EP07105179A EP1870098A3 (fr)	1998-07-10	1999-07-09	Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques

Publications (1)

Publication Number	Publication Date
LU92992I2 true LU92992I2 (fr)	2016-05-09

Family

ID=22352165

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91358C LU91358I2 (fr)	1998-07-10	2007-09-06	Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium
LU92992C LU92992I2 (fr)	1998-07-10	2016-03-07	Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU91358C LU91358I2 (fr)	1998-07-10	2007-09-06	Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium

Country Status (31)

Country	Link
EP (3)	EP2322174B1 (fr)
JP (1)	JP2002520274A (fr)
KR (2)	KR20040078140A (fr)
CN (2)	CN1234357C (fr)
AT (1)	ATE371448T1 (fr)
AU (1)	AU753486B2 (fr)
BE (1)	BE2016C011I2 (fr)
BR (1)	BR9912021A (fr)
CA (2)	CA2336822C (fr)
CY (4)	CY1107779T1 (fr)
CZ (2)	CZ299429B6 (fr)
DE (2)	DE122007000055I1 (fr)
DK (2)	DK2322174T3 (fr)
ES (2)	ES2289814T3 (fr)
FR (1)	FR16C0008I2 (fr)
HU (1)	HU229383B1 (fr)
ID (1)	ID27664A (fr)
IL (3)	IL140665A0 (fr)
LU (2)	LU91358I2 (fr)
NL (2)	NL300290I2 (fr)
NO (2)	NO331802B1 (fr)
NZ (2)	NZ509260A (fr)
PL (1)	PL194604B1 (fr)
PT (2)	PT1096932E (fr)
RU (3)	RU2243768C2 (fr)
SG (1)	SG142116A1 (fr)
SI (2)	SI1096932T1 (fr)
SK (1)	SK285863B6 (fr)
TR (1)	TR200100062T2 (fr)
WO (1)	WO2000002543A2 (fr)
ZA (1)	ZA200100232B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040078140A (ko)	1998-07-10	2004-09-08	노파르티스 아게	발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
NZ511938A (en) *	1998-12-23	2004-02-27	Novartis Ag	Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
CA2371554C (fr) *	1999-04-28	2009-06-09	Shizue Nakagawa	Composition pharmaceutique comportant un antagoniste de l'angiotensine ii pour la prevention, le traitement ou le blocage du developpement de la retinopathie simple et de la retinopathie preproliferative
JP2001089393A (ja)	1999-07-21	2001-04-03	Takeda Chem Ind Ltd	脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
DK1216038T3 (da)	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU2001235364A1 (en)	2000-02-25	2001-09-03	Novo-Nordisk A/S	Tetrahydronaphtalene derivatives and their use
WO2001062740A1 (fr) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Analogues de mibefradil et leur utilisation
PE20020082A1 (es) *	2000-04-12	2002-02-21	Novartis Ag	Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
DE10018401A1 (de)	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
AR033390A1 (es) *	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
BR0108823A (pt) *	2000-12-29	2002-12-10	Osmotica Corp	Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
CN1571668A (zh) *	2001-10-18	2005-01-26	诺瓦提斯公司	At1－受体拮抗剂和心血管药物形成的盐
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
US20040138306A1 (en)	2002-07-25	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
WO2004110354A2 (fr)	2003-05-15	2004-12-23	Roskamp Research, Llc	Methode de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose
MXPA05012299A (es) *	2003-05-16	2006-01-30	Novartis Ag	Composicion farmaceutica que comprende valsartan.
RU2255740C2 (ru) *	2003-07-02	2005-07-10	Научно-исследовательский институт кардиологии Томского научного центра СО РАМН	Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en)	2003-09-05	2005-03-24	Boehringer Ingelheim International Gmbh	Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (fr) *	2003-11-25	2005-06-16	Novartis Ag	Combinaison de composes organiques
WO2005070463A2 (fr) *	2004-01-12	2005-08-04	Sepracor, Inc.	Compositions comprenant du malate de (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation
CN100364532C (zh) *	2004-09-30	2008-01-30	江苏恒瑞医药股份有限公司	包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
WO2006109164A2 (fr)	2005-04-15	2006-10-19	Research & Innovation Soc. Coop. A R.L.	Methode pour prevenir, retarder ou inverser la progression de pathologies associees a un depot amyloide anormal
GT200600371A (es) *	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) *	2005-10-07	2005-11-16	Imp College Innovations Ltd	Biological agents and method
EP1951309A2 (fr) *	2005-11-08	2008-08-06	Novartis AG	Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) *	2006-08-28	2008-07-27	Илья Николаевич Медведев	Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) *	2006-10-10	2009-03-11	한올제약주식회사	시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) *	2007-02-26	2008-11-20	Илья Николаевич Медведев	Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
CN101883564B (zh)	2007-10-05	2013-10-16	阿尔茨海默病学会美国公司	使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
CN101433536A (zh) *	2007-11-12	2009-05-20	北京瑞康医药技术有限公司	含有烟酸氨氯地平和沙坦类药物的治疗组合物
WO2009084003A1 (fr) *	2007-12-31	2009-07-09	Lupin Limited	Compositions pharmaceutiques d'amlodipine et de valsartan
US20100137403A1 (en) *	2008-07-10	2010-06-03	Scott Malstrom	Method for enhancing cognition or inhibiting cognitive decline
RU2382644C1 (ru) *	2008-11-05	2010-02-27	Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) *	2009-05-28	2010-09-10	Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий)	Способ лечения больных гипертрофической кардиомиопатией
SI2536396T1 (sl)	2010-02-16	2017-01-31	KRKA, tovarna zdravil, d.d.,Novo mesto	Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
IT1400309B1 (it)	2010-05-10	2013-05-24	Menarini Int Operations Lu Sa	Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
SG194162A1 (en)	2011-04-12	2013-11-29	Boryung Pharm	Antihypertensive pharmaceutical composition
KR20140057604A (ko)	2011-08-12	2014-05-13	베링거잉겔하임베트메디카게엠베하	고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
JPWO2013147137A1 (ja) *	2012-03-30	2015-12-14	味の素株式会社	心不全の治療剤
CZ2013783A3 (cs)	2013-10-08	2015-04-15	Zentiva, K. S	Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2016073179A2 (fr) *	2014-10-23	2016-05-12	The Trustees Of The University Of Pennsylvania	Nouvelle chronothérapie basée sur les rythmes circadiens
RU2616213C2 (ru) *	2015-07-10	2017-04-13	Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России)	Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
KR102149321B1 (ko) *	2015-10-31	2020-08-28	아이오 테라퓨틱스, 인크.	Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
CN105287550A (zh) *	2015-11-19	2016-02-03	哈尔滨圣吉药业股份有限公司	一种缬沙坦/非洛地平复方制剂及其制备方法
IL297333B2 (en) *	2020-04-17	2025-09-01	Honeybrains Llc	Preparations and methods for treating neuropsychiatric disorders
US20240299405A1 (en) *	2020-05-28	2024-09-12	Hangzhou Qian Biotechnology Ltd	Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4654372A (en) *	1986-01-10	1987-03-31	Warner-Lambert Company	Method for using verapamil for treating stroke
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
EP0443983B1 (fr) *	1990-02-19	1996-02-28	Ciba-Geigy Ag	Composés acylés
US5492904A (en) *	1991-05-15	1996-02-20	E. I. Du Pont De Nemours And Company	Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en)	1991-05-15	1994-09-27	Du Pont	Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (fr) *	1992-03-04	1993-09-16	Abbott Laboratories	Antagonistes des recepteurs de l'angiotensine ii
EP0656905B1 (fr) *	1992-07-27	1997-09-03	Pfizer Inc.	Inhibiteur calcique a base d'un polypeptide extrait de l'agelenopsis aperta
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (fr) *	1993-06-07	2005-04-26	Yoshiyuki Inada	Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
ES2154277T3 (es) *	1993-07-15	2001-04-01	Hoffmann La Roche	Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
US5889020A (en) *	1994-02-08	1999-03-30	Ciba Vision Corporation	Treatment of normotensive glaucoma with angiotensin II antagonists
CA2184712A1 (fr) *	1994-03-17	1995-09-21	Marc De Gasparo	Traitement de la nephropathie diabetique a l'aide de valsartan
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
KR20040078140A (ko)	1998-07-10	2004-09-08	노파르티스 아게	발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제

1999
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 CA CA002336822A patent/CA2336822C/fr not_active Expired - Lifetime
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 CA CA2678722A patent/CA2678722C/fr not_active Expired - Lifetime
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/fr not_active Revoked
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 EP EP07105179A patent/EP1870098A3/fr not_active Withdrawn
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 EP EP99934647A patent/EP1096932B1/fr not_active Revoked
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/fr not_active Ceased
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I2/el unknown
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
2016
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 LU LU92992C patent/LU92992I2/fr unknown
- 2016-03-07 CY CY2016006C patent/CY2016006I1/el unknown
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown

Also Published As

Publication number	Publication date
CY2007026I1 (el)	2009-11-04
ES2552639T3 (es)	2015-12-01
CA2336822C (fr)	2009-11-17
IL140665A (en)	2012-12-31
CY2016006I2 (el)	2016-10-05
NL300290I2 (nl)	2008-11-03
PL345897A1 (en)	2002-01-14
EP2322174B1 (fr)	2015-09-23
NL300800I2 (fr)	2016-07-27
CN1733307A (zh)	2006-02-15
PT1096932E (pt)	2007-09-21
SI2322174T1 (sl)	2015-12-31
SK285863B6 (sk)	2007-10-04
EP1096932A2 (fr)	2001-05-09
IL140665A0 (en)	2002-02-10
NO20010113L (no)	2001-03-09
EP1870098A3 (fr)	2010-07-07
BE2016C011I2 (fr)	2018-12-04
SI1096932T1 (sl)	2008-04-30
CY2016006I1 (el)	2016-10-05
NO2012013I1 (no)	2012-07-30
WO2000002543A2 (fr)	2000-01-20
EP2322174A2 (fr)	2011-05-18
HUP0102828A2 (hu)	2002-04-29
CY2007026I2 (el)	2009-11-04
PL194604B1 (pl)	2007-06-29
ZA200100232B (en)	2002-04-09
CA2336822A1 (fr)	2000-01-20
FR16C0008I1 (fr)	2016-04-15
ID27664A (id)	2001-04-19
HUP0102828A3 (en)	2002-11-28
DE69936992D1 (de)	2007-10-11
SK312001A3 (en)	2001-06-11
EP1096932B1 (fr)	2007-08-29
DK1096932T3 (da)	2007-10-15
LU91358I2 (fr)	2007-11-06
WO2000002543A3 (fr)	2000-06-29
RU2012110522A (ru)	2013-09-27
CZ200187A3 (en)	2001-05-16
CA2678722A1 (fr)	2000-01-20
EP1870098A2 (fr)	2007-12-26
HU229383B1 (en)	2013-11-28
CZ304359B6 (cs)	2014-03-26
NO2012013I2 (no)	2014-10-27
HK1036758A1 (en)	2002-01-18
HK1152897A1 (en)	2012-03-16
DE122007000055I1 (de)	2007-12-13
CN1312715A (zh)	2001-09-12
NZ509260A (en)	2003-09-26
NO331802B1 (no)	2012-04-10
DK2322174T3 (en)	2015-10-12
ES2289814T3 (es)	2008-02-01
CY1107779T1 (el)	2010-07-28
PT2322174E (pt)	2015-10-27
CA2678722C (fr)	2013-08-27
ATE371448T1 (de)	2007-09-15
AU753486B2 (en)	2002-10-17
CZ299429B6 (cs)	2008-07-23
RU2243768C2 (ru)	2005-01-10
NO20010113D0 (no)	2001-01-08
KR100550167B1 (ko)	2006-02-08
DE69936992T2 (de)	2008-03-06
CY1116770T1 (el)	2016-10-05
FR16C0008I2 (fr)	2018-06-08
JP2002520274A (ja)	2002-07-09
CN1234357C (zh)	2006-01-04
TR200100062T2 (tr)	2001-06-21
EP2322174A3 (fr)	2011-07-27
IL213926A0 (en)	2011-07-31
AU5034999A (en)	2000-02-01
BR9912021A (pt)	2001-04-03
NZ527598A (en)	2005-04-29
SG142116A1 (en)	2008-05-28
KR20040078140A (ko)	2004-09-08
NL300290I1 (fr)	2007-11-01
KR20010079517A (ko)	2001-08-22
RU2450813C2 (ru)	2012-05-20

Publication	Publication Date	Title
NO2012013I1 (no)	2012-07-30	Valsartan + Amlodipin
AU2003206738C1 (en)	2020-01-30	Pharmaceutical compositions comprising valsartan and NEP inhibitors
LU92000I2 (fr)	2012-07-16	Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables